MedCity News October 31, 2024
Novo Holdings led the Series A investment in Kivu Bioscience, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary.
It doesn’t matter how well a drug kills cancer cells if the patient doesn’t stay on treatment. Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said Mohit Trikha, president and chief operating officer of Kivu Bioscience. Kivu is developing therapies intended to offer better tolerability and efficacy. The startup emerged from stealth this week, revealing $92 million in financing and plans to bring its lead program into the clinic in 2025.
San Francisco-based Kivu is developing antibody drug conjugates (ADCs), a...
Today's Sponsors
Today's Sponsor